Now showing items 1-6 of 6

    • A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss Events. 

      Ryan, CJ; Kennedy, S; Bajrami, I; Matallanas, D; Lord, CJ (2017-10-11)
      Protein complexes are responsible for the bulk of activities within the cell, but how their behavior and abundance varies across tumors remains poorly understood. By combining proteomic profiles of breast tumors with a ...
    • E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. 

      Horne, HN; Oh, H; Sherman, ME; Palakal, M; Hewitt, SM; Schmidt, MK; Milne, RL; Hardisson, D; Benitez, J; Blomqvist, C; Bolla, MK; Brenner, H; Chang-Claude, J; Cora, R; Couch, FJ; Cuk, K; Devilee, P; Easton, DF; Eccles, DM; Eilber, U; Hartikainen, JM; Heikkilä, P; Holleczek, B; Hooning, MJ; Jones, M; Keeman, R; Mannermaa, A; Martens, JWM; Muranen, TA; Nevanlinna, H; Olson, JE; Orr, N; Perez, JIA; Pharoah, PDP; Ruddy, KJ; Saum, K-U; Schoemaker, MJ; Seynaeve, C; Sironen, R; Smit, VTHBM; Swerdlow, AJ; Tengström, M; Thomas, AS; Timmermans, AM; Tollenaar, RAEM; Troester, MA; van Asperen, CJ; van Deurzen, CHM; Van Leeuwen, FF; Van't Veer, LJ; García-Closas, M; Figueroa, JD (2018-04-26)
      E-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated E-cadherin tumor immunohistochemistry ...
    • E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. 

      Bajrami, I; Marlow, R; van de Ven, M; Brough, R; Pemberton, HN; Frankum, J; Song, F; Rafiq, R; Konde, A; Krastev, DB; Menon, M; Campbell, J; Gulati, A; Kumar, R; Pettitt, SJ; Gurden, MD; Cardenosa, ML; Chong, I; Gazinska, P; Wallberg, F; Sawyer, EJ; Martin, L-A; Dowsett, M; Linardopoulos, S; Natrajan, R; Ryan, CJ; Derksen, PWB; Jonkers, J; Tutt, ANJ; Ashworth, A; Lord, CJ (2018-04)
      The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells ...
    • Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations. 

      Lopez-Knowles, E; Pearson, A; Schuster, G; Gellert, P; Ribas, R; Yeo, B; Cutts, R; Buus, R; Garcia-Murillas, I; Haynes, B; Martin, L-A; Smith, I; Turner, N; Dowsett, M (2019-01)
      BACKGROUND:Several thousand breast cancer patients develop resistance to aromatase inhibitors (AIs) each year in the UK. Rational treatment requires an improved molecular characterisation of resistant disease. MATERIALS ...
    • Molecular mechanism of APC/C activation by mitotic phosphorylation. 

      Zhang, S; Chang, L; Alfieri, C; Zhang, Z; Yang, J; Maslen, S; Skehel, M; Barford, D (2016-05)
      In eukaryotes, the anaphase-promoting complex (APC/C, also known as the cyclosome) regulates the ubiquitin-dependent proteolysis of specific cell-cycle proteins to coordinate chromosome segregation in mitosis and entry ...
    • RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression. 

      Castellano, E; Molina-Arcas, M; Krygowska, AA; East, P; Warne, P; Nicol, A; Downward, J (2016-04-13)
      RAS signalling through phosphoinositide 3-kinase (PI3-Kinase) has been shown to have an essential role in tumour initiation and maintenance. RAS also regulates cell motility and tumour invasiveness, but the role of direct ...